靶向PLD1驱动的分泌通路可减缓染色体3q扩增非小细胞肺癌小鼠肿瘤生长
Targeting lung cancer's cellular shipping system could offer a new way to slow tumor growth
UTHealth Houston团队在PNAS发表研究,发现染色体3q扩增的非小细胞肺癌细胞通过高尔基体高表达PLD1,将促癌物质分泌到细胞外,从而支持肿瘤生长和存活。在小鼠模型中,直接递送至细胞的靶向PLD1药物显著减缓了肿瘤生长,且未引起其他不良健康影响。研究者Xiaochao Tan表示,染色体3q扩增在头颈癌和食管癌中也常见,这些患者或同样受益于靶向高尔基体分泌机制的治疗。
A UTHealth Houston-led team has identified a promising new avenue to curb the growth and spread of tumors associated with hard-to-treat lung and other cancers.
The research is published today in the Proceedings of the National Academy of Sciences and led by Xiaochao Tan, Ph.D., assistant professor in the Department of Integrative Biology and Pharmacology at McGovern Medical School at UTHealth Houston.
The team's findings build on its efforts to better understand the role of the Golgi apparatus in a specific subtype of non-small cell lung cancer, the most common type of lung cancer that is often diagnosed after it has spread to other parts of the body.
"The therapeutic options for this type of lung cancer are minimal. In this study, we were able to identify a weak point in this type of lung cancer," Tan said.
The Golgi apparatus is the part of the cell that modifies, sorts and packages proteins for delivery to other parts of the cell or for secretion outside the cell. Tan's previous work found that lung cancer cells have extra copies of an abnormal piece of DNA known as chromosome 3q, which encodes several proteins associated with the Golgi apparatus.
The current work identified a region of chromosome 3q that contains the gene encoding the enzyme phospholipase D1, or PLD1. Researchers found that lung cancer cells produce unusually high levels of PLD1 and—through the Golgi apparatus—send cancer-promoting materials out of the cell, allowing tumors to grow and survive.
Using mouse models, the team discovered that these cancer cells could be targeted using a drug delivered directly to the cell that curbs its reliance on PLD1. The drug significantly slowed the growth of the tumors in mice without causing any other negative health effects.
The results indicate that targeting the Golgi secretory machinery is a promising treatment option for multiple types of cancer.
"Extra copies of chromosome 3q are common in cancers such as head and neck cancer and esophageal cancer. Therefore, patients with these cancers may also benefit from this treatment," Tan said.
Publication details
Xiaochao Tan et al., PLD1-driven oncogenic secretion creates a therapeutic vulnerability in chromosome 3q–amplified NSCLC, Proceedings of the National Academy of Sciences (2026). DOI: 10.1073/pnas.2532484123
Journal information: Proceedings of the National Academy of Sciences
Who's behind this story?
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Targeting lung cancer's cellular shipping system could offer a new way to slow tumor growth (2026, October 20) retrieved 20 October 2026 from https://medicalxpress.com/news/2026-10-lung-cancer-cellular-shipping-tumor.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com